ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
23 Oktober 2024 - 1:00PM
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage
oncology company focused on developing treatments that address
mechanisms of therapeutic resistance, today announced the company
presented a poster highlighting certain best-in-class properties of
ORIC-114, a brain penetrant, orally bioavailable, irreversible
EGFR/HER2 inhibitor, to treat EGFR exon 20 insertions and other
atypical mutations at the EORTC-NCI-AACR Symposium on Molecular
Targets and Cancer Therapeutics.
“Preclinical data presented today underscore
ORIC-114’s superior potency and selectively across EGFR mutational
classes compared to other EGFR inhibitors,” said Lori Friedman,
PhD, chief scientific officer. “These results build on clinical
findings that highlight ORIC-114’s potential best-in-class profile,
showing notable systemic and CNS responses, along with a favorable
safety profile, even in heavily pre-treated NSCLC patients. We are
continuing to evaluate ORIC-114 in multiple Phase 1b expansion
cohorts for NSCLC patients with EGFR exon 20, HER2 exon 20, and
atypical EGFR mutations, with updated data expected in the first
half of 2025.”
Poster presentation
details:
ORIC-114, a highly selective, brain penetrant
EGFR and HER2 inhibitor, demonstrates best-in-class properties
against exon 20 insertions and other atypical EGFR mutations
ORIC-114 previously demonstrated systemic and
intracranial clinical responses in heavily pre-treated patients
with EGFR and HER2 exon 20 insertion mutations. Key findings of
this poster presentation:
- Demonstrates regressions in all
EGFR mutant in vivo models tested, including cell-derived
xenografts, patient-derived xenografts and intracranial models that
encompass exon 20 insertion and atypical mutant models. An in vivo
model with complex atypical mutant EGFR dosed with ORIC-114 notably
shows 100% tumor regressions and all tumors experienced a complete
response.
- In an expanded preclinical
comparative analysis of exon 20 insertion, atypical PACC and other
mutations, overall ORIC-114 is the most potent across EGFR
mutational classes whilst displaying comparative wild-type
selectivity in cell-based assays, relative to firmonertinib,
zipalertinib, lazertinib and BDTX-1535.
- In head-to-head comparisons with
firmonertinib, zipalertinib, lazertinib and BDTX-1535, ORIC-114 has
superior kinome selectivity with no off-target kinase liabilities
identified.
- Shows complete molecular responses
in ctDNA from patients with EGFR exon 20 insertion and PACC
mutations from Phase 1 dose escalation study. Evidence of molecular
responses observed across dose escalation cohorts supports broad
therapeutic window for ORIC-114.
- ORIC-114 is a promising therapeutic
candidate with best-in-class potential for patients with non-small
cell lung cancer harboring exon 20 insertions and atypical
mutations in EGFR, including those presenting with active CNS
metastases, and is being evaluated in a global clinical trial
(NCT05315700).
About ORIC-114ORIC-114 is a
highly selective, brain penetrant, orally bioavailable,
irreversible inhibitor that selectively targets EGFR exon 20, HER2
exon 20 and EGFR atypical mutations, making it a promising
therapeutic candidate to address the unmet medical need of having
both meaningful systemic as well as CNS antitumor activity.
About ORIC Pharmaceuticals,
Inc. ORIC Pharmaceuticals is a clinical stage
biopharmaceutical company dedicated to improving patients’ lives
by Overcoming Resistance In Cancer. ORIC’s
clinical stage product candidates include (1) ORIC-114, a brain
penetrant inhibitor that selectively targets EGFR exon 20, HER2
exon 20 and EGFR atypical mutations, being developed across
multiple genetically defined cancers, (2) ORIC-944, an allosteric
inhibitor of the polycomb repressive complex 2 (PRC2) via the EED
subunit, being developed for prostate cancer, and (3) ORIC-533, an
orally bioavailable small molecule inhibitor of CD73, a key node in
the adenosine pathway believed to play a central role in resistance
to chemotherapy- and immunotherapy-based treatment regimens, being
developed for multiple myeloma. Beyond these three product
candidates, ORIC® is also developing multiple precision medicines
targeting other hallmark cancer resistance mechanisms. ORIC has
offices in South San Francisco and San Diego, California. For more
information, please go to www.oricpharma.com, and follow us
on X or LinkedIn.
Cautionary Note Regarding
Forward-Looking StatementsThis press release contains
forward-looking statements as that term is defined in Section 27A
of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Statements in this press release that are not
purely historical are forward-looking statements. Such
forward-looking statements include, among other things, statements
regarding the best-in-class properties of ORIC-114; the continued
clinical development of ORIC-114; the potential advantages of
ORIC-114 and ORIC’s other product candidates and programs; timing
of updated data from the clinical trial of ORIC-114; development
plans for ORIC’s product candidates and programs; and statements by
the company’s chief scientific officer. Words such as “believes,”
“anticipates,” “plans,” “expects,” “intends,” “will,” “goal,”
“potential” and similar expressions are intended to identify
forward-looking statements. The forward-looking statements
contained herein are based upon ORIC’s current expectations and
involve assumptions that may never materialize or may prove to be
incorrect. Actual results could differ materially from those
projected in any forward-looking statements due to numerous risks
and uncertainties, including but not limited to: risks associated
with the process of discovering, developing and commercializing
drugs that are safe and effective for use as human therapeutics and
operating as an early clinical stage company; ORIC’s ability to
develop, initiate or complete preclinical studies and clinical
trials for, obtain approvals for and commercialize any of its
product candidates; changes in ORIC’s plans to develop and
commercialize its product candidates; the potential for clinical
trials of ORIC’s product candidates to differ from preclinical,
initial, interim, preliminary or expected results; negative impacts
of health emergencies, economic instability or international
conflicts on ORIC’s operations, including clinical trials; the risk
of the occurrence of any event, change or other circumstance that
could give rise to the termination of ORIC’s license and
collaboration agreements or its clinical trial collaboration and
supply agreements; the potential market for ORIC’s product
candidates, and the progress and success of competing therapeutics
currently available or in development; ORIC’s ability to raise any
additional funding it will need to continue to pursue its business
and product development plans; regulatory developments in the
United States and foreign countries; ORIC’s reliance on third
parties, including contract manufacturers and contract research
organizations; ORIC’s ability to obtain and maintain intellectual
property protection for its product candidates; the loss of key
scientific or management personnel; competition in the industry in
which ORIC operates; general economic and market conditions; and
other risks. Information regarding the foregoing and additional
risks may be found in the section titled “Risk Factors” in ORIC’s
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (the “SEC”) on August 12, 2024, and ORIC’s
future reports to be filed with the SEC. These forward-looking
statements are made as of the date of this press release, and ORIC
assumes no obligation to update the forward-looking statements, or
to update the reasons why actual results could differ from those
projected in the forward-looking statements, except as required by
law.
Contact:Dominic Piscitelli,
Chief Financial
Officerdominic.piscitelli@oricpharma.cominfo@oricpharma.com
Oric Pharmaceuticals (NASDAQ:ORIC)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Oric Pharmaceuticals (NASDAQ:ORIC)
Historical Stock Chart
Von Dez 2023 bis Dez 2024